Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
November 01 2023 - 7:05AM
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology
company pursuing development of targeted therapies for oncology,
today announced that Brian Sullivan, Chairman, Chief Executive
Officer, and Co-founder of Celcuity, will present and be available
for one-on-one investor meetings at the following investor
conferences:
- A formal
presentation at the Stifel 2023 Healthcare Conference in New York
at 4:10 p.m. ET on Tuesday, November 14, 2023. A live webcast will
be available using this weblink:
https://wsw.com/webcast/stifel83/celc/2056478; and
- A fireside chat at
the Jefferies London Healthcare Conference at 8:00 a.m. GMT / 4:00
a.m. ET on Thursday, November 16, 2023. A live webcast will be
available using this weblink:
https://wsw.com/webcast/jeff287/celc/1825156.
About Celcuity
Celcuity is a clinical-stage biotechnology company
focused on development of targeted therapies for treatment of
multiple solid tumor indications. The company's lead therapeutic
candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor.
Its mechanism of action and pharmacokinetic properties are highly
differentiated from other currently approved and investigational
therapies that target PI3K or mTOR alone or together. A Phase 3
clinical trial, VIKTORIA-1, evaluating gedatolisib in combination
with fulvestrant with or without palbociclib in patients with
HR+/HER2- advanced breast cancer is currently enrolling patients.
More detailed information about the VIKTORIA-1 study can be found
at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201,
evaluating gedatolisib in combination with darolutamide in patients
with metastatic castration resistant prostate cancer, is expected
to be initiated in the first quarter of 2024. The company's
CELsignia companion diagnostic platform is uniquely able to analyze
live patient tumor cells to identify new groups of cancer patients
likely to benefit from already approved targeted therapies. Further
information about Celcuity can be found at Celcuity.com. Follow us
on LinkedIn and Twitter.
View source version of release on GlobeNewswire.com
Contacts:
Celcuity Inc.Brian Sullivan,
bsullivan@celcuity.comVicky Hahne, vhahne@celcuity.com(763)
392-0123
ICR WestwickeMaria Yonkoski,
maria.yonkoski@westwicke.com (203) 682-7167
Celcuity (NASDAQ:CELC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Celcuity (NASDAQ:CELC)
Historical Stock Chart
From Jul 2023 to Jul 2024